Brain SPECT Following Cialis (Tadalafil ) Administration

Brain SPECT Perfusion Imaging Following Cialis (Tadalafil ) Administration in Patients With Vascular Risk Factors

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01374347

Acronym

CIALIS

Enrollment

Registered

2011-06-15

Start date

2011-05-31

Completion date

2012-07-31

Last updated

2016-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Change in Brain Perfusion

Brief summary

The study will be an open label one and will include 30 patients who underwent ischemic stroke 3 month to 3 years prior to the study. All patients will undergone a baseline brain SPECT perfusion study. 15 patients will take one dose of 20 mg cialis, and will have a second brain SPECT 24 hours after cialis administration. 15 other patients (age and risk factor matched) will be prescribed 5 mg of cialis once daily for 7 days, and a second SPECT study will be performed 24 hours after the last dose.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

35 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Male and female patients in the age range of 35-75 years.

Exclusion criteria

1. known allergic reaction to TF 2. Medical contraindication to use TF 3. Hemorrhagic stroke including intracerebral hemorrhage and subarachnoid hemorrhage 4. Acute stroke or cardiac ischemic event up to 3 month prior to study. 5. Other neurological brain diseases including degenerative diseases, multiple sclerosis, brain tumors, post severe brain injury (TBI) and migraine headache. 6. Sensory aphasia. 7. Cognitive impairment with disability to sign a consent form.Patients' Assessment

Outcome results